Lawrence  Steinman net worth and biography

Lawrence Steinman Biography and Net Worth

Director of BioAtla
Dr. Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and was Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on what provokes relapses and remissions in Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO), and the quest for antigen specific therapy. He is developing a small molecule therapeutic currently in clinical trials for Huntington’s Disease. He was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohn’s Disease. Dr. Steinman graduated from Dartmouth College, Magna Cum Laude in Physics. His MD is from Harvard Medical School. He was a post-doctoral fellow in Chemical Immunology at the Weizmann Institute of Science. After a neurology residency at Stanford University he joined the faculty in 1980. He has received numerous honors, including the John M. Dystel Prize in 2004, the Javits Neuroscience Investigator Award from the NINDS twice, and the Charcot Prize in MS research. Dr. Steinman is a member of the National Academy of Sciences and the National Academy of Medicine. Dr. Steinman holds 41 patents. He cofounded several biotech companies including Neurocrine Biosciences, Bayhill Therapeutics (now Tolerion), Nuon Therapeutics, Transparency Life Sciences and Atreca. He was a Director of Centocor from 1988 until its sale to Johnson and Johnson.

What is Lawrence Steinman's net worth?

The estimated net worth of Lawrence Steinman is at least $132,298.96 as of December 19th, 2023. Dr. Steinman owns 38,459 shares of BioAtla stock worth more than $132,299 as of March 29th. This net worth estimate does not reflect any other investments that Dr. Steinman may own. Learn More about Lawrence Steinman's net worth.

How do I contact Lawrence Steinman?

The corporate mailing address for Dr. Steinman and other BioAtla executives is , , . BioAtla can also be reached via phone at 858-558-0708 and via email at [email protected]. Learn More on Lawrence Steinman's contact information.

Has Lawrence Steinman been buying or selling shares of BioAtla?

Lawrence Steinman has not been actively trading shares of BioAtla during the last quarter. Most recently, on Tuesday, December 19th, Lawrence Steinman bought 20,000 shares of BioAtla stock. The stock was acquired at an average cost of $2.05 per share, with a total value of $41,000.00. Following the completion of the transaction, the director now directly owns 38,459 shares of the company's stock, valued at $78,840.95. Learn More on Lawrence Steinman's trading history.

Who are BioAtla's active insiders?

BioAtla's insider roster includes Guy Levy (Director), Jay Short (CEO), Eric Sievers (Insider), Scott Smith (President), Lawrence Steinman (Director), Christian Vasquez (Insider), and Richard Waldron (CFO). Learn More on BioAtla's active insiders.

Are insiders buying or selling shares of BioAtla?

During the last year, BioAtla insiders bought shares 5 times. They purchased a total of 116,800 shares worth more than $263,176.00. The most recent insider tranaction occured on December, 26th when Director Sylvia Mcbrinn bought 4,000 shares worth more than $9,320.00. Insiders at BioAtla own 8.4% of the company. Learn More about insider trades at BioAtla.

Information on this page was last updated on 12/26/2023.

Lawrence Steinman Insider Trading History at BioAtla

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2023Buy20,000$2.05$41,000.0038,459View SEC Filing Icon  
11/2/2021Sell450$30.00$13,500.00View SEC Filing Icon  
9/15/2021Sell450$36.82$16,569.00View SEC Filing Icon  
8/16/2021Sell450$40.60$18,270.00View SEC Filing Icon  
7/15/2021Sell450$38.29$17,230.50View SEC Filing Icon  
See Full Table

Lawrence Steinman Buying and Selling Activity at BioAtla

This chart shows Lawrence Steinman's buying and selling at BioAtla by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioAtla Company Overview

BioAtla logo
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Read More

Today's Range

Now: $3.44
Low: $3.33
High: $3.55

50 Day Range

MA: $2.50
Low: $1.88
High: $3.46

2 Week Range

Now: $3.44
Low: $1.24
High: $4.07

Volume

703,773 shs

Average Volume

484,902 shs

Market Capitalization

$164.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02